The Developmental Therapeutics Program, an established program of the Cancer Center, contributes to more effective treatment of malignant disease through e spectrum of basic end translational research.
The AIMS ere to 1) define cellular pathways involved in survival end proliferation in order to improve understanding of response to established treatments end identify new therapeutic targets;2) elucidate the mechanisms of action of novel anticancer agents end identify biochemical changes resulting in resistance to these agents;3) evaluate potential genetic contributions to efficacy and toxicity of anticancer treatments;end 4) assess the toxicity end initial activity of selected treatments in early phase clinical trials, with an emphasis on correlative studies that assess pharmacokinetics, pharmacogenetics end biological effects of agents in tumor cells. Forty-five members from 17 departments end divisions contribute to this effort, with total funding of $23.3M ($11.9M peer-reviewed, with 60.3% from NCI and 89.3% from the NIH overall). Since the lest competitive renewal, the program has generated 724 publications, 19% end 57% reflecting intra- end inter-programmatic collaborations, respectively. Notable accomplishments include demonstration that 1) the temoxifen metabolite endoxifen, which bypasses an important metabolic block in some patients, has activity in preclinical studies end early phase clinical trials;2) PARP inhibitors kill BRCA1/2-mutent cells through e process that involves activation of the nonhomologous end-joining pathway, yielding e unique responder/no responder hypothesis that is being tested clinically;end 3) FKBP51, MMSET end cereblon ere important determinants of response to various therapies. Leadership of the program is provided by Scott Keufmenn, MD, PhD, end Zhenkun Lou, PhD. The program makes extensive use of Shared Resources, especially the cell analysis, proteomics, pathology research, gene analysis, pharmacology end pharmacy facilities, as well as the Clinical Research Office. Future goals of the program include the establishment of e focus on oncogene-induced metabolic changes as therapeutic targets in cancer, growth of a nascent screening/drug discovery effort, end encouragement of additional genomically guided trials to follow recently opened studies.
|Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33|
|Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9|
|Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34|
|Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8|
|Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97|
|Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70|
|Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38|
|Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43|
|Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508|
|Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7|
Showing the most recent 10 out of 340 publications